COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Onco-Innovations completes successful 300g scale-up batch of A83B4C63, achieving 99.3% purity for API under ONC010 PNKP Inhibitor Technology. Dave Antony appointed as CFO -
-
-
-
COMMUNIQUÉ DE PRESSE
2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
2CRSi responds to Grizzly Research Report, reaffirms business operations authenticity. Investor webinar on June 19, 2026, 6:00 PM CET. Details on revenues, projects, and geographic distribution clarified -
COMMUNIQUÉ DE PRESSE
2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
2CRSi responds in detail to the allegations in the report by Grizzly Research LLC, reaffirming the legitimacy of its operations. The company clarifies points raised by shareholders -
COMMUNIQUÉ DE PRESSE
2CRSi SA: 2CRSi répond point par point au rapport de Grizzly Research et réaffirme la réalité de son activité
2CRSi SA répond point par point au rapport de Grizzly Research et réaffirme la réalité de son activité. La société conteste les allégations et clarifie sa situation financière, industrielle et ses contrats -
![Logo de [UNKNOWN]](https://logos.symex.be/img/.jpg)
